---
figid: PMC7188631__gr1_lrg
figtitle: Conversion of Sofosbuvir pro-drug to the triphosphate drug in vivo
organisms:
- NA
organisms_ner:
- NA
pmcid: PMC7188631
filename: gr1_lrg.jpg
figlink: pmc/articles/PMC7188631/figure/fig1/
number: F1
caption: Conversion of Sofosbuvir pro-drug to the triphosphate drug in vivo. This
  UMP prodrug requires the removal of phosphate protection to enter a pathway to yield
  sofosbuvir triphosphate, the pharmacologically active antiviral compound.
papertitle: 'Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We
  Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?.'
reftext: Babak Sayad, et al. Arch Med Res. 2020 Aug;51(6):577-581.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9283559
figid_alias: PMC7188631__F1
figtype: Figure
redirect_from: /figures/PMC7188631__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7188631__gr1_lrg.html
  '@type': Dataset
  description: Conversion of Sofosbuvir pro-drug to the triphosphate drug in vivo.
    This UMP prodrug requires the removal of phosphate protection to enter a pathway
    to yield sofosbuvir triphosphate, the pharmacologically active antiviral compound.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - nucleosidyl
  - diphosphate
  - nucleoside
  - OH F
  - OH
  - 2-F,Me-UTP
  - Nucleoside
  - Nucleoside monophosphate
  - nucleoside triphosphate
  - Sofosbuvir
---
